Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1989 1
1990 1
1991 2
1992 1
1993 1
1995 2
1996 1
1998 1
1999 2
2000 3
2001 4
2002 11
2003 9
2004 4
2005 9
2006 12
2007 27
2008 44
2009 36
2010 34
2011 42
2012 52
2013 64
2014 63
2015 24
2016 14
2017 23
2018 46
2019 85
2020 90
2021 90
Text availability
Article attribute
Article type
Publication date

Similar articles for PMID: 29097481

682 results
Results by year
Filters applied: . Clear all
Page 1
C.E.R.A. maintains stable hemoglobin in Latin American patients on dialysis.
Bastos K, Lucarelli LA, De Francesco-Daher E, Filho RP, Henríquez C, Espinoza B, Villanueva I, Schwedt E, Schiavelli R, Correa-Rotter R. Bastos K, et al. Int Urol Nephrol. 2013 Oct;45(5):1355-64. doi: 10.1007/s11255-012-0272-3. Epub 2012 Sep 19. Int Urol Nephrol. 2013. PMID: 22990412 Free PMC article. Clinical Trial.
Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study.
Canaud B, Mingardi G, Braun J, Aljama P, Kerr PG, Locatelli F, Villa G, Van Vlem B, McMahon AW, Kerloëguen C, Beyer U; STRIATA Study Investigators. Canaud B, et al. Nephrol Dial Transplant. 2008 Nov;23(11):3654-61. doi: 10.1093/ndt/gfn320. Epub 2008 Jun 27. Nephrol Dial Transplant. 2008. PMID: 18586762 Free PMC article. Clinical Trial.
Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, Ehrhard P, Beyer U; PROTOS Study Investigators. Sulowicz W, et al. Clin J Am Soc Nephrol. 2007 Jul;2(4):637-46. doi: 10.2215/CJN.03631006. Epub 2007 May 23. Clin J Am Soc Nephrol. 2007. PMID: 17699476 Free article. Clinical Trial.
Renal prognoses by different target hemoglobin levels achieved by epoetin beta pegol dosing to chronic kidney disease patients with hyporesponsive anemia to erythropoiesis-stimulating agent: a multicenter open-label randomized controlled study.
Tsuruya K, Hayashi T, Yamamoto H, Hase H, Nishi S, Yamagata K, Nangaku M, Wada T, Uemura Y, Ohashi Y, Hirakata H; RADIANCE-CKD Study Investigators. Tsuruya K, et al. Clin Exp Nephrol. 2021 May;25(5):456-466. doi: 10.1007/s10157-020-02005-4. Epub 2021 Jan 7. Clin Exp Nephrol. 2021. PMID: 33411115 Clinical Trial.
Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A, Salifu MO, Lunde NM, Bansal V, Fishbane S, Dougherty FC, Beyer U; Ba16285 Study Investigators. Besarab A, et al. Clin Ther. 2007 Apr;29(4):626-39. doi: 10.1016/j.clinthera.2007.04.014. Clin Ther. 2007. PMID: 17617286 Clinical Trial.
682 results